Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.63 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.63 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.63 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.63 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.63 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337186 | 1.00 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7346307 | 0.82 | SPPL2A (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7337192 | 0.78 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7346380 | 0.76 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7343159 | 0.68 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4987183 | 0.63 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4411858 | 0.62 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4991645 | 0.62 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15216925 | 0.60 | XIAP (0.82) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7689272 | 0.60 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432944-B1 | ARYLACETAMIDOALANYL DERIVATIVES OF BENZODIAZEPINONES ARE USEFUL FOR INHIBITION OF EXTRACELLULAR DEPOSITION OF BETA-AMYLOID PEPTIDE, THUS TREATS AMYLOIDOSIS, ALZHEIMER'S DISEASE AND DOWN'S SYNDROME | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-13 | — | — | US | disclosed |